Agomelatine Monotherapy for Autism-A Case Report

Ahmed Naguy; Saxby Pridmore; Mohammed A Jamali; Alaa Eisa Hasan; Bibi Alamiri

Agomelatine Monotherapy for Autism-A Case Report

Psychopharmacol Bull. 2022 Oct 27;52(4):100-103.

Authors

Ahmed Naguy¹, Saxby Pridmore², Mohammed A Jamali³, Alaa Eisa Hasan⁴, Bibi Alamiri⁵

Affiliations

¹ Naguy, MBBCh, MSc, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwait.
² Pridmore, MBBS, BMedSc, MD, FRANZCP, FAFPHM, FAChAM, FFPMAZCP, AM,Senior Professor of Psychiatry, University of Tasmania, Hobart, Australia.
³ Jamali, MD, MSc, General Adult Psychiatrist, KCMH, Kuwait.
⁴ Hasan, MSc (Psychol), Psychotherapist, School Psychiatry Clinic, MOE, Az-Zahra, State of Kuwait.
⁵ Alamiri, MD, ABPN, ScD, Consultant Psychiatrist, Chairperson, Al-Manara CAP Centre, KCMH, Kuwait, and Tufts University, Medford, United States.

PMID: 36339272
PMCID: PMC9611798

Abstract

ASD is commonly associated with a host of challenging behaviours. Pharmacotherapy is indicated if psycho-social and educational interventions fail. Atypical antipsychotics have the strongest evidence-base so far, with both risperidone and aripiprazole are FDA-approved. Unfortunately, their use is fraught with metabolic and neuro-hormonal side effects. Here, authors report on a case of ASD/mild ID with behavioural dyscontrol that failed multiple psychotropic trials and ultimately responded favourably to agomelatine monotherapy. This was achieved with excellent tolerability. This might open new venues in such complicated cases.

Keywords: ASD; agomelatine; behavioral dyscontrol.

Publication types

Case Reports

MeSH terms

Antipsychotic Agents* / adverse effects
Aripiprazole / adverse effects
Autism Spectrum Disorder* / drug therapy
Autistic Disorder* / chemically induced
Autistic Disorder* / drug therapy
Humans
Risperidone / therapeutic use

Substances

agomelatine
Aripiprazole
Risperidone
Antipsychotic Agents